1. Development, Therapy, Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes;Kontoghiorghe CN,2016
2. Deferiprone: a review of its clinical potential in iron overload in β-thalassaemia major and other transfusion-dependent diseases;Barman Balfour JA,1999
3. A.J.C.m.c. Kolnagou, Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combinations;Kontoghiorghes GJ,2005
4. Analytical approaches for the determination of deferiprone and its iron (III) complex: Investigation of binding affinity based on liquid chromatography-mass spectrometry (LC-ESI/MS) and capillary electrophoresis-frontal analysis (CE/FA);Asmari M,2020
5. Synthesis of a New Nanocomposite Based on Natural Asphalt and Its Application as a High-Performance and Eco-friendly Platform for the Electrochemical Determination of Deferiprone;Farokhi S,2023